GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific antibodies, and antibody-drug conjugates targeting GPRC5D are advancing rapidly through clinical pipelines. With limited cross-reactivity to normal tissues, GPRC5D presents a promising target, enhancing its commercial potential.

LAS VEGAS, July 3, 2025 /PRNewswire/ -- DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging GPRC5D-directed therapies, market share of individual therapies, and current and forecasted GPRC5D-directed therapies market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Takeaways from the GPRC5D-directed Therapies Market Report

• As per DelveInsight's analysis, the total market size of GPRC5D-directed therapies in the 7MM is expected to surge significantly by 2034.
• As per DelveInsight's estimates, the total market size in the US for multiple myeloma was ~USD 15 billion in 2024, which is expected to show positive growth.
• Currently, TALVEY (talquetamab-tgvs), approved in August 2023, is the first and the only approved GPRC5D-directed therapy in the market.
• In the US, there were around 33,700 incident cases of multiple myeloma in 2024, which was the highest among seven major markets.
• Leading GPRC5D-directed therapies companies, such as Bristol Myers Squibb (Juno Therapeutics), AstraZeneca, Oricell, CARsgen Therapeutics, Sanofi, Jiangsu Simcere Pharmaceutical, AbbVie, and others, are developing novel GPRC5D-directed therapies that can be available in the GPRC5D-directed therapies market in the coming years. 
• Some of the key GPRC5D-directed therapies in the pipeline include Arlocabtagene autoleucel (BMS-986393), AZD0305, OriCAR-017, CT071, SAR446523, SIM0500, and others.
• In June 2025, CARsgen Therapeutics presented a Phase I study of CT071 for the treatment of newly diagnosed multiple myeloma at the European Hematology Association (EHA) website.

Discover which indication is expected to grab the major GPRC5D-directed therapies market share @ GPRC5D-directed Therapies Market Report

GPRC5D-directed Therapies Market Dynamics

The GPRC5D-directed therapies market is emerging as a significant focus within the landscape of multiple myeloma treatment. GPRC5D is an orphan receptor predominantly expressed on malignant plasma cells, with limited expression in normal tissues, making it an attractive therapeutic target. Its expression is independent of BCMA, allowing it to serve as a complementary or alternative target, particularly in patients who have relapsed after BCMA-directed treatments. This has driven a wave of innovation in bispecific antibodies, ADCs, and CAR-T cell therapies targeting GPRC5D.

The competitive landscape is rapidly evolving, with multiple biotech and pharmaceutical companies advancing GPRC5D-targeted candidates through preclinical and clinical pipelines. Notably, companies such as Johnson & Johnson (via its teclistamab platform) and Legend Biotech are exploring GPRC5D-directed bispecifics and CAR-T constructs, respectively. Early-phase clinical trials have shown promising efficacy in relapsed/refractory multiple myeloma (RRMM) populations, even among those previously treated with BCMA-targeted agents. The ability of GPRC5D-targeting therapies to produce deep and durable responses, with manageable toxicity profiles, is a key factor fueling investor interest and partnerships in this space.

Market dynamics are further shaped by the unmet clinical need in late-line multiple myeloma settings. As more patients receive BCMA therapies earlier in their treatment journeys, resistance and relapse rates have prompted the search for alternative targets like GPRC5D. Regulatory agencies, including the FDA and EMA, have shown openness to accelerated pathways for novel immunotherapies in RRMM, creating favorable conditions for GPRC5D-focused assets. Additionally, the ongoing development of allogeneic platforms and off-the-shelf bispecific antibodies is poised to enhance patient access and reduce logistical burdens compared to autologous CAR-T approaches.

However, challenges remain in this emerging space. Differentiation among therapies targeting the same antigen will be crucial, as companies aim to optimize dosing schedules, minimize on-target off-tumor toxicities, and address manufacturing scalability. Pricing and reimbursement strategies will also play a critical role, particularly as competition intensifies and cost-effectiveness comes under scrutiny from payers and health systems.

Looking forward, the GPRC5D-directed therapy market is expected to expand significantly over the next 10 years, driven by a combination of clinical validation, rising relapse rates in existing treatment paradigms, and an influx of new therapeutic modalities. Success in this domain will likely depend on the ability to integrate GPRC5D-targeted agents into combination regimens, leverage companion diagnostics to optimize patient selection, and establish long-term safety and efficacy through robust Phase III trials and real-world evidence.

GPRC5D-directed Therapies Treatment Market 

GPRC5D is highly expressed in multiple myeloma cells and is found in abundance within the bone marrow of patients diagnosed with multiple myeloma or smoldering multiple myeloma. Currently, TALVEY (talquetamab-tgvs), approved in August 2023, is the first and the only approved GPRC5D-directed therapy in the market. TALVEY is a novel, first-in-class bispecific T-cell engager that simultaneously binds to the CD3 receptor on T cells and GPRC5D, which is present on multiple myeloma cells, non-cancerous plasma cells, and certain healthy epithelial tissues, particularly in the skin and tongue. It is administered subcutaneously on a weekly or biweekly basis following an initial step-up dosing phase, giving physicians the flexibility to tailor dosing schedules to individual patient needs.

Learn more about the FDA-approved GPRC5D-directed therapies @ Approved GPRC5D-directed Therapies 

Key Emerging GPRC5D-directed Therapies and Companies

Some of the major emerging key players in the GPRC5D market include CARsgen Therapeutics (CT071), Oricell (OriCAR-017), Bristol-Myers Squibb (Arlocabtagene autoleucel), AstraZeneca (AZD0305), and others.

OriCAR-017 is an innovative CAR T cell therapy developed to target GPRC5D, aimed at treating relapsed or refractory multiple myeloma. Developed using Oricell Therapeutics' advanced proprietary technology, OriCAR-017 demonstrates unique advantages in terms of binding strength, cell persistence, tumor-fighting capability, and safety. It received Investigational New Drug (IND) approval from the U.S. FDA in January 2024, following earlier approval by China's NMPA in 2023.

BMS-986393 is an autologous CAR T cell therapy also directed at GPRC5D. Currently under evaluation in the Phase II QUINTESSENTIAL trial for relapsed/refractory multiple myeloma, the therapy is expected to yield key data in 2026. At the ASH 2023 conference, updated results from its Phase I trial highlighted durable responses, manageable safety, and clinical activity in patients regardless of prior BCMA-targeted treatment exposure.

The anticipated launch of these emerging therapies are poised to transform the GPRC5D-directed therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GPRC5D-directed therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about GPRC5D-directed therapies clinical trials, visit @ GPRC5D-directed Therapies Treatment 

GPRC5D-directed Therapies Overview

GPRC5D, an orphan G-protein-coupled receptor located on chromosome 12p13, lacks a known ligand. It has emerged as a validated therapeutic target in multiple myeloma. Early-phase clinical trials involving T–cell–reducing therapies aimed at GPRC5D have demonstrated encouraging efficacy along with tolerable safety profiles, although these findings still require confirmation in Phase III studies.

This receptor is highly expressed in multiple myeloma cells and is prevalent in the bone marrow of patients with both active and smoldering disease. Furthermore, its mRNA levels are notably higher in multiple myeloma compared to other hematologic malignancies. The selective overexpression of GPRC5D in myeloma cells makes it an attractive candidate for immune effector cell–based therapies. Targeting GPRC5D, either as a standalone treatment or in combination with other anti-myeloma agents, could broaden the therapeutic landscape, particularly for patients who require novel mechanisms of action, whether to delay the use of BCMA-targeted therapies, overcome poor responses or antigen loss, or address clonal variability.

Although GPRC5D and BCMA are both expressed on CD138+ myeloma cells, their expression is not interdependent, making them distinct therapeutic targets. Importantly, GPRC5D expression remains stable even when BCMA is lost, a known resistance mechanism in some relapsed patients, supporting the rationale for combining GPRC5D- and BCMA-directed T-cell therapies to better manage the disease's heterogeneity.

GPRC5D-directed Therapies Epidemiology Segmentation

The GPRC5D-directed therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:

• Total Cases in Selected Indications (Multiple Myeloma) for GPRC5D-directed Therapies
• Total Eligible Patient Pool in Selected Indications for GPRC5D-directed Therapies
• Total Treated Cases in Selected Indications for GPRC5D-directed Therapies

Scope of the GPRC5D-directed Therapies Market Report

• GPRC5D-directed Therapies Therapeutic Assessment: GPRC5D-directed Therapies current marketed and emerging therapies
• GPRC5D-directed Therapies Market Dynamics: Conjoint Analysis of Emerging GPRC5D-directed Therapies Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, GPRC5D-directed Therapies Market Access and Reimbursement

Discover more about GPRC5D-directed therapies in development @ GPRC5D-directed Therapies Clinical Trials

Table of Contents

Related Reports

Multiple Myeloma Market

Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., among others.

CAR-T Market

CAR-T Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CAR-T companies, including Gilead Sciences, Inc., Novartis AG, Caribou Biosciences, Inc., Aurora Biopharma, Bristol-Myers Squibb Company, CARsgenTherapeutics Co., Ltd, JW Therapeutics (Shanghai) Co., Ltd., Cartesian Therapeutics, Inc., Johnson & Johnson Services, Inc. (Janssen Global Services, LLC), among others.

Antibody Drug Conjugates Market

Antibody Drug Conjugates Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ADC companies, including NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., among others.

Bispecifics/Trispecifics Market

Bispecifics/Trispecifics Market Forecast and Competitive Landscape – 2035 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key bispecifics/trispecifics companies, including Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur  
info@delveinsight.com
+14699457679

Logo:  https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg